The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Kaydan M.A.

Alexeev Psychiatric Hospital No. 1

Bravve L.V.

Alexeev Psychiatric Hospital No. 1

Clinical and psychopathological features of treatment-resistant schizophrenia

Authors:

Kaydan M.A., Bravve L.V.

More about the authors

Read: 1388 times


To cite this article:

Kaydan MA, Bravve LV. Clinical and psychopathological features of treatment-resistant schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(2):43‑50. (In Russ.)
https://doi.org/10.17116/jnevro202512502143

Recommended articles:
Pathogenetic inte­rrelations of hypo­gonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23
PANSS six-factor model. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):28-34
Clinical and immu­nological rela­tionships in patients with early schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42
Modern concepts of sleep disturbances asso­ciated with mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):7-12
Factors supporting chro­nic inflammation in mental illness. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):7-15

References:

  1. Diniz E, Fonseca L, Rocha D, et al. Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates. Braz J Psychiatry. 2023;45(5):448-458.  https://doi.org/10.47626/1516-4446-2023-3126
  2. Rocca P, Montemagni C, Zappia S, et al. Negative symptoms and everyday functioning in schizophrenia: a cross-sectional study in a real-world setting. Psychiatry Res. 2014;218(3):284-289.  https://doi.org/10.1016/j.psychres.2014.04.018
  3. Kennedy JL, Altar CA, Taylor DL, et al. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29(2):63-76.  https://doi.org/10.1097/YIC.0b013e32836508e6
  4. Iasevoli F, Giordano S, Balletta R, et al. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. Prog Neuropsychopharmacol Biol Psychiatry. 2016;65:34-48.  https://doi.org/10.1016/j.pnpbp.2015.08.010
  5. Mosolov SN. Resistance to psychopharmacotherapy and methods of overcoming it. Psychiatry and psychopharmacotherapy. 2002;4(4):132-136. (In Russ.).
  6. Siskind D, Siskind V, Kisely S. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. Can J Psychiatry. 2017;62(11):772-777.  https://doi.org/10.1177/0706743717718167
  7. Potkin SG, Kane JM, Correll CU, et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020;6(1):1.  https://doi.org/10.1038/s41537-019-0090-z
  8. Howes OD, McCutcheon R, Agid O, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2017;174(3):216-229.  https://doi.org/10.1176/appi.ajp.2016.16050503
  9. Kane JM, Agid O, Baldwin ML, et al. Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. J Clin Psychiatry. 2019;80(2):18com121232019. https://doi.org/10.4088/JCP.18com12123
  10. Demjaha A, Lappin JM, Stahl D, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47(11):1981-1989. https://doi.org/10.1017/S0033291717000435
  11. Takeuchi H, Siu C, Remington G, et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology. 2019;44(6):1036-1042. https://doi.org/10.1038/s41386-018-0278-3
  12. Chan SKW, Chan HYV, Honer WG, et al. Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders. Schizophr Bull. 2021;47(2):485-494.  https://doi.org/10.1093/schbul/sbaa145
  13. Farooq S, Agid O, Foussias G, et al. Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification. Schizophr Bull. 2013;39(6):1169-1172. https://doi.org/10.1093/schbul/sbt137
  14. Dold M, Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. Evid Based Ment Health. 2014;17(2):33-37.  https://doi.org/10.1136/eb-2014-101813
  15. Snezhnevskiy AV. Shizofreniya: Klinika i patogenez. Pod red. Snezhnevskogo A.V. M.: Meditsina. 1969;463. (In Russ.).
  16. Foucher JR, Gawlik M, Roth JN, et al. Wernicke-Kleist-Leonhard phenotypes of endogenous psychoses: a review of their validity. Dialogues Clin Neurosci. 2020;22(1):37-49.  https://doi.org/10.31887/DCNS.2020.22.1/jfoucher
  17. Barone A, De Prisco M, Altavilla B, et al. Disorganization domain as a putative predictor of Treatment Resistant Schizophrenia (TRS) diagnosis: A machine learning approach. J Psychiatr Res. 2022;155:572-578.  https://doi.org/10.1016/j.jpsychires.2022.09.044
  18. Pomytkin AN, Tikhonov DV, Kaleda VG. Augmentation of therapy for resistant schizophrenia by rhythmic transcranial magnetic stimulation. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(8):107-114. (In Russ.). https://doi.org/10.17116/jnevro2023123081107
  19. Fonseca de Freitas D, Agbedjro D, Kadra-Scalzo G, et al. Clinical correlates of early onset antipsychotic treatment resistance. J Psychopharmacol. 2022;36(11):1226-1233. https://doi.org/10.1177/02698811221132537
  20. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318-378.  https://doi.org/10.3109/15622975.2012.696143
  21. Leucht S. Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J Clin Psychiatry. 2014;75 Suppl 1:8-14.  https://doi.org/10.4088/JCP.13049su1c.02
  22. ICD-11, the 11th Revision of the International Classification of Diseases. Date of the application 27.08.2024. https://www.who.int/classifications/icd/en/
  23. Piskarev MV, Lobanova VM, Ilyina NA. Periodic catatonia in schizophrenia spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(8):98-106. (In Russ.). https://doi.org/10.17116/jnevro202312308198
  24. Druzhinina TA. Katatonicheskaya forma techeniya shizofrenii. Trudy Vsesoyuznoj nauchno-prakticheskoj konf., posvyashchennoj 100-letiyu so dnya rozhdeniya S.S. Korsakova i aktual’nym voprosam psihiatrii. 1955;165. (In Russ.).
  25. Kahlbaum C. Die Katatonie oder das Spannungsirresein. 1874.
  26. Ey H, Bernard P, Brisset C. Manuel de psychiatrie. 2010;1166.
  27. Compton MT, Fantes F, Wan CR, et al. Abnormal movements in first-episode, nonaffective psychosis: Dyskinesias, stereotypies, and catatonic-like signs. Psychiatry Research. 2015;226(1):192-197.  https://doi.org/10.1016/j.psychres.2014.12.048
  28. Ilina NA, Zaharova NV. Long-term dyskinetic remissions in shiftlike schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(12):17-23. (In Russ.).
  29. Akopova IL. Typology of oneiroid catatonia. S.S. Korsakov Journal of Neurology and Psychiatry. 1965;11:1710-1716. (In Russ.).

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.